Study findings indicated a transition from IV to enteral triazole therapy as a feasible option for pediatric patients with invasive candidiasis.

The trial, conducted in the United Kingdom, found that a procalcitonin-guided algorithm didn't reduce IV antibiotic duration ...

Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...

The latest confirmation likely reflects follow-up testing of a San Francisco child whose exposure to the virus is still under ...

A groundbreaking UK study in The Lancet has examined whether an additional blood test called procalcitonin (PCT) could safely shorten the time children spend on intravenous (IV) antibiotics in ...

Australia imports about 90 per cent of its medicine, and this makes us incredibly vulnerable to any supply disruption. But it ...

BioArctic announces US FDA accepts Eisai’s BLA for subcutaneous maintenance dosing of Leqembi: Stockholm Wednesday, January 15, 2025, 13:00 Hrs [IST] BioArctic AB (publ) announc ...

( MENAFN - JCN NewsWire) FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the treatment of Early Alzheimer's disease LEQEMBI is the only ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding three areas of its ...